Hong Kong Verily Health Technology Group has officially announced a strategic partnership with a renowned direct sales and micro-business team in Mainland China. This move marks a significant deepening of its expansion and strategic adjustment in the Asian market. According to the agreement, the direct sales team will gain business expansion rights in the Asian region, as well as pre-IPO stock subscription rights and dividend rights from Hong Kong Verily.
This collaboration is a crucial part of Hong Kong Verily’s strategy in the Asian market, aimed at promoting its health tech products through the network and resources of the Mainland direct sales team, thereby enhancing brand recognition and market share in Asia. The CEO of Hong Kong Verily Health Technology Group stated that through this model, the company can more effectively reach its target customer base while strengthening cooperation and communication with other health tech entities in the region.
The leader of the Mainland direct sales team also expressed high recognition and anticipation for this collaboration, believing that it will not only provide unprecedented growth opportunities for team members but also bring more health benefits to consumers through Hong Kong Verily’s high-end tech products. The inclusion of pre-IPO stock subscription rights and dividend rights in the cooperation agreement further incentivizes the direct sales team to participate in the long-term development of Hong Kong Verily.
To ensure the smooth progress of the collaboration, Hong Kong Verily has established a dedicated project team responsible for daily communication and business coordination with the direct sales team, ensuring that all business objectives can be effectively achieved. Additionally, Hong Kong Verily plans to hold multiple product showcases and health tech forums in the coming months to enhance interaction with Asian consumers and strengthen brand influence.
Industry analysts believe that Hong Kong Verily’s choice to collaborate with the Mainland direct sales team is an important adjustment to its global market strategy, which will not only enhance its competitiveness in the Asian market but also help maintain its leading position in the global health tech industry. As the collaboration deepens, it is expected to have a positive impact on Hong Kong Verily’s performance and market share.
With the implementation of the cooperation agreement, Hong Kong Verily and the Mainland direct sales team will jointly open a new chapter in the Asian market, bringing more high-quality health tech products and services to consumers in the region and promoting the continued development and prosperity of the Asian health tech market.